The characteristics of sago starch exhibit remarkable resemblances to those of cassava, potato, and maize starches. This review intends to discuss and summarize the synthesis and characterization of sodium starch glycolate (SSG) from sago starch as a superdisintegrant from published journals using keywords in PubMed, Scopus, and ScienceDirect databases by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020). There are many methods for synthesizing sodium starch glycolate (SSG). Other methods may include the aqueous, extrusion, organic solvent slurry, and dry methods. Sago starch is a novel form of high-yield starch with significant development potential. After cross-linking, the phosphorus content of sago starch increases by approximately 0.3 mg/g, corresponding to approximately one phosphate ester group per 500 anhydroglucose units. The degree of substitution (DS) of sodium starch glycolate (SSG) from sago ranges from 0.25 to 0.30; in drug formulations, sodium starch glycolate (SSG) from sago ranges from 2% to 8% w/w. Higher levels of sodium starch glycolate (SSG) (2% and 4% w/w) resulted in shorter disintegration times (within 1 min). Sago starch is more swellable and less enzymatically digestible than pea and corn starch. These investigations demonstrate that sago starch is a novel form of high-yield starch with tremendous potential for novel development as superdisintegrant tablets and capsules.

This study focused on optimizing sago-starch-derived sodium starch glycolate (SSG) as a superdisintegrant using a Response Surface Methodology (RSM). The aim was to enhance the formulation performance by achieving an optimal degree of substitution (DS) in the synthesis of SSG from sago starch and evaluating its performance in mefenamic acid tablet formulation. The SSG was synthesized using an organic solvent slurry method, which involves crosslinking starch with sodium trimetaphosphate (STMP) and substituting it with sodium monochloroacetate (SMCA). The reaction conditions, including the temperature, SMCA ratio, and reaction time, were optimized using the RSM. The optimal conditions were identified as a temperature range of 45–55 °C, an SMCA ratio of 0.75–1.5, and a reaction time of 120–240 min. The maximum predicted DS value was 0.24, with a validated DS value of 0.246 ± 0.021. The SSG-containing mefenamic acid formulation met USP standards and showed a superior disintegration time compared to the existing SSG. The optimized SSG derived from sago starch can be effectively used as a superdisintegrant in pharmaceutical formulations, offering a sustainable and economically viable alternative source of SSG. This contributes to the development of more effective drug delivery systems and promotes sustainable agriculture in Indonesia.

Hydroxypropyl cellulose (HPC) is extensively utilized as a binder and in controlled-release matrices, yet its production predominantly relies on high-purity α-cellulose derived from wood or cotton, which subjects supply chains to sustainability issues and fluctuations in feedstock prices. Annually, sugarcane bagasse, estimated at approximately 490–600 million tons annualy, presents a scalable, residue-based cellulose source for HPC production within circular bioeconomy frameworks. This review compiles findings from 106 peer-reviewed studies on cellulose and HPC derived from bagasse, addressing synthesis methods, structure–property relationships, and pharmaceutical applications. Published studies indicate that HPC derived from bagasse can achieve a degree of substitution (DS 1.87) compared to commonly reported commercial wood-pulp HPC grades (DS 1.8–2.5). Crystallinity reduction relative to commercial HPC has been proposed based on the lower crystallinity of the underlying bagasse cellulose feedstock, but this has not yet been directly measured for the hydroxypropylated product. Beyond performance, bagasse is an agricurtural residue available at negligible feedstock cost, in contrast to the established market prices of purified wood pulp and cotton linter (US$18–25 per kg) used in commercial HPC manufacturing. Life-cycle assessments of bagasse valorization pathways have similarly reported favorable environmental profiles relative to conventional biomass feedstocks. However, no dedicated techno-economic or life-cycle assessment specific to pharmaceutical-grade HPC production from bagasse has been published, and these potential sustainability and cost advantages therefore remain to be formally validated at industrial scale. Key challenges remain in regulatory acceptance, impurity control, batch-to-batch standardization, and scaling up etherification under pharmaceutical good manufacturing practice (GMP) constraints. Overall, the reviewed literature positions sugarcane bagasse (SCB)-derived HPC as a promising candidate for combining excipient performance with potential sustainability and cost benefits, necessitating targeted process optimization and qualification studies to expedite industrial adoption.